Researchers have identified a protein that powers the virulence of the bacteria that causes gonorrhea, opening the possibility of a new target for antibiotics and, even better, a vaccine.
The findings, published today in PLOS Pathogens, are especially important since the microbe, Neisseria gonorrhoeae, is considered a “superbug” because of its resistance to all classes of antibiotics available for treating infections.
Gonorrhea, a sexually transmitted disease that results in 78 million new cases worldwide each year, is highly damaging if untreated or improperly treated.
It can lead to endometritis, pelvic inflammatory disease, ectopic pregnancy, epididymitis and infertility. Babies born to infected mothers are at increased risk of blindness.
“The infections very often are silent,” said Oregon State University researcher Aleksandra Sikora. “Up to 50 percent of infected women don’t have symptoms, but those asymptomatic cases can still lead to some very severe consequences for the patient’s reproductive health, miscarriage or premature delivery.”
The need for better antibiotic therapy, and a vaccine, is pressing. N. gonorrhoeae strains resistant to the last effective treatment options have emerged, and failures in treatment are occurring.
Sikora and her research team at the OSU/OHSU College of Pharmacy and Ann Jerse’s lab at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, collaborated to discover a novel lipoprotein that N. gonorrhoeae uses to defeat the body’s first line of innate immune defense.
The body relies on enzymes known as lysozymes that, as their name suggests, thwart bacteria by causing their cell wall to lyse, or break apart. Lysozymes are abundant both in epithelial cells, which make up the tissue on the outside of organs and the inside of body cavities, and in the phagocytic cells that protect the body by ingesting foreign particles and bacteria.
In turn, many gram-negative bacteria – characterized by their cell envelope that includes a protective outer membrane – have developed ways of defeating lysozymes. Prior to the work by Sikora’s team, however, only one lysozyme-fighting protein had been discovered in the Neisseria genus.
Now that new targets have been identified, they can be explored as bullseye candidates for new antibiotics or a vaccine – if the lysozyme inhibitor can itself be inhibited, then the bacteria’s infection-causing ability is greatly reduced.
Sikora and her collaborators named the new protein SliC, short for surface-exposed lysozyme inhibitor of c-type lysozyme.
Studying SliC’s function in culture as well as in a gonorrhea mouse model – mice were infected with N. gonorrhoeae, then checked for SliC expression at one, three and five days – researchers determined the protein was essential to bacterial colonization because of its anti-lysozyme role.
“This is the first time an animal model has been used to demonstrate a lysozyme inhibitor’s role in gonorrhea infection,” Sikora said. “Together, all of our experiments show how important the lysozyme inhibitor is. This is very exciting.”
The Latest on: Gonorrhea
[google_news title=”” keyword=”gonorrhea” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gonorrhea
- Blue Earth County sees slight dip in STI cases,on April 26, 2024 at 3:14 pm
MANKATO — Blue Earth County saw a slight dip in chlamydia and gonorrhea cases in 2023 from 2022, the Minnesota Department of Health reported this week.
- 10 States with the Highest STD Rateson April 26, 2024 at 8:22 am
These are the top states that have the highest STD rates according to recent data obtained by the CDC. It surprises ...
- Study: High percentage of chlamydia and gonorrhea patients not receiving CDC recommended treatmenton April 25, 2024 at 10:39 pm
Chlamydia and gonorrhea are the two most common sexually transmitted infections (STIs) in the United States, impacting 2.4 million in 2021, and the number is rising.
- Study reports chlamydia and gonorrhea more likely to be treated per CDC guidelines in certain populationson April 25, 2024 at 1:38 pm
Chlamydia and gonorrhea are the two most common sexually transmitted infections (STIs) in the United States, impacting 2.4 million in 2021, and the number is rising.
- Sexually transmitted diseases in Minnesota are down, but HIV and newborn syphilis cases are upon April 25, 2024 at 10:55 am
Increases in HIV infections, and in cases of syphilis passed from mothers to newborns, marred an otherwise hopeful decline in sexually transmitted diseases in Minnesota last year. Minnesota's state ...
- Gonorrhea cases continue to rise, particularly among womenon April 25, 2024 at 4:03 am
The number of young people with a gonorrhea infection continues to soar, with an increase of 31% over the last year, latest figures from public health institute RIVM have shown. Some 13,853 cases of ...
- Gonorrhea cases up 78% among young women, alarming Dutch authoritieson April 25, 2024 at 1:14 am
Healthcare workers in the Netherlands discovered an alarming increase in the number of women diagnosed with a gonorrhea infection last year. While statistics from all population groups showed 31 ...
- Ex-youth center resident testifies that counselor went from trusted father figure to horrific abuseron April 18, 2024 at 5:30 pm
The man who blew the lid off decades of abuse allegations at New Hampshire’s youth detention center continued testifying at his civil trial Thursday ...
- Former N.H. youth center resident testifies about sexual, physical abuse at YDCon April 18, 2024 at 3:02 pm
I’m constantly paying for what they did,” said David Meehan, whose lawsuit against the state sparked more than 1,100 other former residents to file lawsuits of their own.
via Bing News